Sprint: DTx last mile delivery: HCPs and Patient adoption

 While the DTx market is growing exponentially, the scale of usage from the physician and patient cohorts remains low. For example, even though German DiGA has 24 approved products so far, their prescription and adoption have not taken off yet. Join this series of 2 meetings to discuss with other senior leaders the following:  

 SESSION 1 (Took place on January 6th)
- How do we make HCPs aware of DTx solutions? Should we use the same model used for drugs, or what are the alternatives?
- DTx integration into physicians’ tools (like EMR, CDSS, etc) and workflow so that they are able to prescribe/recommend a DTx - Challenges and best practices
- Why would physicians want to prescribe/recommend a DTx product? What are their motivations? Is being reimbursed a must so that a physician wants to recommend/prescribe a product?

SESSION 2 (February 3rd)
- How do we activate patients to start using DTx solutions? What are their motivations? Is being reimbursed a must to get patient adoption? 
- How do we ensure the proper patient onboarding for DTx products?
- Once they have started using a DTx solution, how do we ensure patient retention? How to continuously improve patient engagement? - Best practices & Challenges (e.g engaging all demographic groups, long term engagement, etc)